Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms

Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms

Oncolytic viruses (OV) and second mitochondrial activator of caspase (Smac)-mimetic compounds (SMC) synergistically kill cancer cells directly. Here, the authors show that SMC and OV therapies combination also synergize in vivo by promoting anticancer immunity through an increase in CD8+ T-cell resp...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Dae-Sun Kim, Himika Dastidar, Chunfen Zhang, Franz J. Zemp, Keith Lau, Matthias Ernst, Andrea Rakic, Saif Sikdar, Jahanara Rajwani, Victor Naumenko, Dale R. Balce, Ben W. Ewanchuk, Pankaj Tailor, Robin M. Yates, Craig Jenne, Chris Gafuik, Douglas J. Mahoney
Format: article
Langue:EN
Publié: Nature Portfolio 2017
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/f1edf28f5df34c7d87c29319c84877f7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:Oncolytic viruses (OV) and second mitochondrial activator of caspase (Smac)-mimetic compounds (SMC) synergistically kill cancer cells directly. Here, the authors show that SMC and OV therapies combination also synergize in vivo by promoting anticancer immunity through an increase in CD8+ T-cell response.

Documents similaires